Key Takeaways:
- Nomura reaffirmed Buy on WUXI BIO with a HKD50.54 price target
- The USD400 million buyback plan signals management sees undervaluation
- Stock surged 5% after losing 17% over the past 60 days
Back
WUXI BIO surges 5% as Nomura buyback call flags 44% upside
WUXI BIO rose 5% to HKD35.02 after Nomura reiterated its Buy rating, citing a USD400 million buyback plan as a signal of undervaluation.
"Together with the plan to repurchase up to 407 million shares for no more than USD400 million, this voluntary business update demonstrates solid operations and signals that the stock is undervalued," Nomura analysts said in a note.
The stock opened 1.08% higher and surged as much as 6.4% to an intraday high of HKD35.46, with 18.8 million shares changing hands worth HKD658 million. Nomura maintained its price target of HKD50.54, implying 44% upside from the last traded price. Management also provided high revenue growth targets for 2027 through 2029, with encouraging trends in manufacturing revenue, a key area of investor focus.
WUXI BIO has lost 17% over the past 60 days, compared with a 5% decline in the Hang Seng Index over the same period. The buyback and business update represent a positive signal from management regarding undervaluation, Nomura said.
The reaffirmed guidance and buyback plan signal management's confidence in the company's growth trajectory. Investors will watch for further execution on the share repurchase program and whether the 2027-2029 revenue targets materialize to close the gap with the broader market.
This article is for informational purposes only and does not constitute investment advice.
[1] WUXI BIO Up 5% as Nomura Says Reiterated Full-yr Revenue Growth Guidance and Buyback Are Positive Signals of Undervaluation[2] WUXI BIO Up 5% as Nomura Says Reiterated Full-yr Revenue Growth Guidance and Buyback Are Positive Signals of Undervaluation - AASTOCKS.com[3] WUXI BIO (02269.HK) Up 5% as Nomura Says Reiterated Full-year Revenue Growth Guidance and Buyback Signal Undervaluation - AASTOCKS.com
